Dr. Ron Vender

Dermatologist, Hamilton, ON

Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis.

He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. He is Honorary Staff at St. Joseph’s Healthcare in Hamilton ON. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis.

He represents Canada on several Global educational steering committees as well as international advisory boards. He has published many peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally.

11:25 AM - 12:10 PM Open Session

Nov 25

Let’s talk GPP!

In the broad category of psoriasis lies many diseases, including the broadly known and prevalent plaque psoriasis, as well as the far less common, and rare, conditions such as guttate, inverse, erythrodermic and pustular psoriasis. Despite sharing the term psoriasis, generalized pustular psoriasis (GPP) is a distinct condition whose disease pathway is different than the far more common plaque psoriasis. This open session will serve to provide a comprehensive review of GPP, including disease mechanisms and patient prevalence/predispositions. The conversation will then dive into the burden of disease and truly call to light the unmet needs that currently exists with patients suffering with GPP. Those in attendance will gain a better understanding of this rare disease.

Learning Objectives

  1. Increase awareness of generalized pustular psoriasis (GPP) as a different and distinct condition from plaque psoriasis
  2. Raise awareness and highlight the burden of disease on patients with GPP